CalciMedica, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. CalciMedica is a clinical-stage biopharmaceutical company developing CRAC channel inhibitors, led by Auxora. It has not generated product revenue. The 2023 comparison is affected by the March 2023 reverse merger: pre-merger statements reflect Private CalciMedica on a stand-alone basis, so periods are not fully comparable.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Revenue | None | None |
| Research and development | $2.944 million | $6.491 million |
| General and administrative | $2.823 million | $15.849 million |
| Total operating expenses / operating loss | $5.767 million | $22.340 million |
| Other income, net | $5.897 million | $3.052 million |
| Net income (loss) | $0.130 million | $(19.288) million |
| Cash used in operating activities | $4.715 million | $5.355 million |
Q1 2024 net income primarily reflected a $5.590 million noncash gain from revaluing warrant liabilities and $0.307 million of other income, including interest income; it does not indicate product profitability. The company recorded no income tax provision or benefit.
At March 31, 2024, cash and cash equivalents were $6.755 million and short-term investments were $18.955 million, totaling $25.710 million. Current assets were $26.604 million, current liabilities $4.287 million, and total assets $27.134 million. Total liabilities were $9.887 million, including a $5.600 million warrant liability; the filing reports no funded debt on the balance sheet. Accumulated deficit was $145.934 million.
Cash flow included $13.103 million net cash used in investing activities, reflecting investment purchases and maturities, and $19.043 million provided by financing, principally from the 2024 private placement. Cash increased by $1.225 million to $6.755 million; short-term investments increased as cash was placed in securities.
Changes versus the prior comparable period
- Operating expenses fell 74%. R&D declined 55%, mainly because Q1 2023 included merger-related stock-award acceleration and severance charges; clinical-trial-related activity was broadly flat.
- G&A declined 82%, principally because Q1 2023 included $8.6 million of accelerated stock compensation and $4.1 million of merger-related severance. Professional services rose by $0.9 million in Q1 2024.
- Net results improved by $19.418 million, from a $19.288 million loss to $0.130 million income, largely reflecting lower one-time expenses and warrant fair-value movements. In Q1 2023, other income included fair-value gains on warrants and convertible notes.
- Q1 2024 financing included a private placement that generated $20.4 million gross and approximately $19.0 million net. The transaction issued 4,985,610 common shares and warrants, with additional pre-funded warrants issued to certain investors.
Outlook, risks and notable items
- Management expects available cash, cash equivalents and short-term investments to fund operations into the second half of 2025 and support Auxora milestones in acute pancreatitis, AIPT and acute kidney injury through 2024 and the first half of 2025. The liquidity note separately states resources are expected to cover at least one year following issuance of the statements. These are estimates, and management says current resources will not fund candidates through regulatory approval or all planned programs.
- Management expects continuing losses and increased R&D, G&A and capital needs. Additional funding will be required; future equity financing could dilute shareholders, while debt or collaborations could impose restrictions or require rights to be relinquished.
- CARPO Phase 2b acute pancreatitis topline results were expected in Q2 2024, with a Phase 3 trial planned for 2025. A significant portion of CARPO was conducted in India, and regulators may not accept foreign trial data or may require additional trials.
- The FDA cleared the KOURAGE IND for Auxora in acute kidney injury with acute hypoxemic respiratory failure; enrollment was expected to begin in Q2 2024 and data in 2025. The company also expects additional CRSPA data in 2025 and plans an IND submission for CM6336 in 2025.
- Key risks include clinical-trial failure or delay, patient enrollment, regulatory uncertainty, reliance on third-party manufacturers and CROs, and dependence on additional capital. One component of clinical supply is sourced from a single supplier in China.
- The company reported $5.6 million of Level 3 warrant liabilities and significant fair-value estimate sensitivity. The filing reports no pending litigation expected to have a material adverse effect; disclosure controls were deemed effective at a reasonable assurance level.
Investor facts to verify
- Whether CARPO topline results were subsequently reported and how the final data compare with the company’s expectations.
- Actual cash burn and whether the stated runway remains achievable as trial activity and expenses change.
- The terms, potential dilution and fair-value accounting of the private-placement warrants, pre-funded warrants and remaining financing capacity.
- Regulatory acceptance of CARPO data, including data collected in India, and progress and timelines for KOURAGE and other stated clinical milestones.
- Manufacturing supply continuity and any changes to clinical-trial budgets, enrollment, or program plans.